Skip to main content
    N

    Niagen Bioscience, Inc. (NAGE)

    Official site

    CONSUMER DEFENSIVE • BIOTECHNOLOGY • NASDAQ

    $2.01
    -0.05 (-2.66%)

    Market Cap: $163.54M

    Last updated: Nov 17, 2026 at 11:03 AM ET

    Niagen Bioscience, Inc. (NAGE) Financials: Revenue, Profit and Cash Flow

    Updated Nov 4, 2026. Financial statements from company filings, amounts in US dollars.

    Niagen Bioscience reported revenue of $129.42M for the fiscal year ended Dec 31, 2025, up 29.9% from the year before. That year, net income was $17.38M with a net margin of 13.4%, operating cash flow was $13.50M and free cash flow was $13.21M. The quarter ended Sep 30, 2026 had revenue of $27.19M and net income of -$1.17M.

    Revenue and Margins

    The operating margin was 12.6% in the fiscal year ended Dec 2025, the highest of the 9 years shown with an operating margin. Over the 9 years to Dec 2025, revenue grew from $21.66M, a compound annual rate of 22.0%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$129.42M+29.9%64.3%12.6%13.4%
    Dec 2024$99.60M+19.2%61.8%7.8%8.6%
    Dec 2023$83.57M+16.0%60.8%-6.7%-5.9%
    Dec 2022$72.05M+6.8%59.4%-25.9%-23.0%
    Dec 2021$67.45M+13.8%61.5%-40.1%-40.2%
    Dec 2020$59.26M+28.0%59.5%-33.5%-33.6%
    Dec 2019$46.29M+46.7%55.7%-67.6%-69.4%
    Dec 2018$31.56M+48.8%50.9%-105.1%-105.6%
    Dec 2017$21.20M-2.1%49.4%-77.2%-53.7%
    Dec 2016$21.66MN/A48.0%-13.4%-13.5%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, net income rose 103.3% from the year before. In the quarter ended Sep 2026, the company posted a net loss after a profit in the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$129.42M$99.60M$83.57M$72.05M$67.45M$59.26M$46.29M$31.56M$21.20M$21.66M
    Cost of revenue$46.23M$38.01M$32.79M$29.25M$25.96M$23.98M$20.52M$15.50M$10.72M$11.27M
    Gross profit$83.19M$61.59M$50.78M$42.80M$41.49M$35.27M$25.77M$16.05M$10.48M$10.39M
    Research and development$6.33M$6.02M$4.96M$4.83M$3.83M$3.42M$4.42M$5.48M$4.01M$2.52M
    Operating income$16.28M$7.73M-$5.60M-$18.63M-$27.07M-$19.85M-$31.30M-$33.17M-$16.38M-$2.91M
    Net income$17.38M$8.55M-$4.94M-$16.54M-$27.13M-$19.93M-$32.15M-$33.32M-$11.38M-$2.93M
    EBITDA$16.85M$8.54M-$4.57M-$16.74M-$25.45M-$18.34M-$29.78M-$32.40M-$15.66M-$2.49M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$27.19M$29.79M$31.47M$33.84M$33.99M$31.12M$30.48M$29.13M$25.58M$22.74M$22.15M$21.20M
    Gross profit$17.11M$19.31M$19.98M$21.70M$21.93M$20.23M$19.33M$18.20M$16.24M$13.69M$13.46M$12.94M
    Operating income-$1.59M$700.00K$1.58M$4.09M$4.24M$3.19M$4.77M$7.11M$1.60M-$256.00K-$731.00K-$168.00K
    Net income-$1.17M$963.00K$6.32M$4.13M$4.58M$3.61M$5.06M$7.18M$1.88M-$15.00K-$492.00K$114.00K
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $1.00M by $63.79M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$106.41M$68.28M$54.96M$54.06M$57.84M$38.36M$40.25M$42.23M$62.72M$19.75M
    Current assets$96.81M$64.10M$49.53M$46.57M$48.91M$32.22M$33.52M$36.53M$57.18M$15.74M
    Cash and equivalents$64.79M$44.66M$27.32M$20.44M$28.02M$16.70M$18.81M$22.62M$45.39M$1.64M
    Total liabilities$29.87M$22.18M$26.51M$25.39M$26.11M$21.93M$19.80M$15.05M$8.89M$9.78M
    Short-term debt$1.00M$994.00K$702.00K$696.00K$548.00K$620.00K$853.00K$173.00K$196.00K$255.46K
    Shareholder equity$76.53M$46.09M$28.46M$28.67M$31.73M$16.42M$20.45M$27.18M$53.83M$9.97M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$108.69M$106.59M$114.33M$106.41M$98.14M$91.53M$81.34M$68.28M$56.52M$54.03M$54.08M$54.96M
    Total liabilities$25.62M$24.06M$32.00M$29.87M$27.46M$27.33M$25.99M$22.18M$22.15M$23.32M$25.13M$26.51M
    Cash and equivalents$69.51M$66.74M$66.55M$64.79M$64.29M$60.47M$55.62M$44.51M$32.40M$27.89M$27.57M$27.17M
    Shareholder equity$83.07M$82.53M$82.33M$76.53M$70.68M$64.19M$55.34M$46.09M$34.37M$30.72M$28.95M$28.46M
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 97.9% of operating cash flow. Share repurchases came to 1.9% of it.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow$13.50M$12.11M$7.12M-$15.10M-$24.16M-$10.60M-$20.44M-$20.91M-$9.80M-$2.94M
    Capital expenditures$292.00K$163.00K$148.00K$334.00K$409.00K$124.00K$743.00K$1.32M$1.17M$1.50M
    Free cash flow$13.21M$11.95M$6.97M-$15.43M-$24.57M-$10.72M-$21.18M-$22.23M-$10.97M-$4.44M
    Share repurchases$251.00K$0N/AN/AN/AN/A$565.00KN/AN/AN/A
    Investing cash flow-$292.00K-$143.00K-$143.00K-$334.00K-$409.00K-$165.00K-$249.00K-$1.77M$4.60M-$1.72M
    Financing cash flow$6.92M$5.37M-$90.00K$7.65M$36.09M$8.65M$16.88M-$90.00K$48.95M$754.27K
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow$2.63M$2.77M-$1.19M$679.00K$3.69M$1.25M$7.88M$8.58M$3.50M-$264.00K$295.00K$649.00K
    Capital expendituresN/AN/A$61.00K$101.00K$24.00K$135.00K$32.00K$69.00K$41.00K$12.00K$41.00K$21.00K
    Free cash flowN/AN/A-$1.25M$578.00K$3.67M$1.11M$7.85M$8.51M$3.45M-$276.00K$254.00K$628.00K
    Last 12 quarters

    Frequently Asked Questions About NAGE

    What is Niagen Bioscience's annual revenue?

    Niagen Bioscience reported revenue of $129.42M for the fiscal year ended Dec 31, 2025.

    How fast is Niagen Bioscience's revenue growing?

    Revenue was up 29.9% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 21.6%.

    Is Niagen Bioscience profitable?

    Yes. Niagen Bioscience reported net income of $17.38M for the fiscal year ended Dec 31, 2025, with a net margin of 13.4%.

    How much free cash flow does NAGE generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $13.50M minus capital expenditures of $292.00K produced free cash flow of $13.21M.

    How much debt does Niagen Bioscience have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $1.00M and cash and equivalents of $64.79M.